Izumi Daisuke, Ishimoto Takatsugu, Miyake Keisuke, Eto Tsugio, Arima Kota, Kiyozumi Yuki, Uchihara Tomoyuki, Kurashige Junji, Iwatsuki Masaaki, Baba Yoshifumi, Sakamoto Yasuo, Miyamoto Yuji, Yoshida Naoya, Watanabe Masayuki, Goel Ajay, Tan Patrick, Baba Hideo
Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Center for Gastrointestinal Research and Center for Translational Genomics and Oncology, Baylor Scott and White Research Institute and Charles A. Sammons Cancer Center, Dallas, Texas, USA.
Stem Cells. 2017 Sep;35(9):2027-2036. doi: 10.1002/stem.2668. Epub 2017 Jul 31.
The cancer stem cell (CSC) paradigm suggests that tumors are organized hierarchically. Chugai previously established an LGR5 human colorectal cancer (CRC) stem-cell-enriched cell line (colorectal CSCs) that expresses well-accepted colorectal CSC markers and that can dynamically switch between proliferative and drug-resistant noncycling states. We performed this study to elucidate the molecular mechanisms responsible for evading cell death in colorectal CSCs mediated by anticancer agents. During the cell cycle arrest caused by anticancer agents, we found that c-Myc expression was substantially decreased in colorectal CSCs. The c-Myc expression alterations were mediated by upregulation of F-box/WD repeat-containing protein 7 (FBXW7), as evidenced through FBXW7-small interfering RNA knockdown experiments that resulted in enhanced cell sensitivity to anticancer agents. Upregulation of FBXW7 following drug treatment was not evident in commercially available cancer cell lines. Colorectal CSCs were induced to differentiation by Matrigel and fetal bovine serum. Differentiated CSCs treated with anticancer agents did not show upregulation of FBXW7 and were more sensitive to irinotecan (CPT-11), highlighting the potential CSC-specific nature of our data. The FBXW7 over-expression was further validated in resected liver metastatic sites in CRC patients after chemotherapy. In conclusion, our study revealed that a CSC-specific FBXW7-regulatory mechanism is strongly associated with resistance to chemotherapeutic agents. Inhibition of FBXW7-upregulation in CSCs following chemotherapy may enhance the response to anticancer agents and represents an attractive strategy for the elimination of colorectal CSCs. Stem Cells 2017;35:2027-2036.
癌症干细胞(CSC)模式表明肿瘤是分层组织的。中外制药公司先前建立了一种富含LGR5人类结直肠癌(CRC)干细胞的细胞系(结直肠癌CSCs),该细胞系表达公认的结直肠癌CSC标志物,并且能够在增殖和耐药的非循环状态之间动态切换。我们进行这项研究以阐明介导抗癌药物诱导的结直肠癌CSCs逃避细胞死亡的分子机制。在抗癌药物导致的细胞周期停滞期间,我们发现结直肠癌CSCs中c-Myc的表达大幅下降。c-Myc表达的改变是由含F-box/ WD重复蛋白7(FBXW7)的上调介导的,通过FBXW7小干扰RNA敲低实验证明,该实验导致细胞对抗癌药物的敏感性增强。药物处理后FBXW7的上调在市售癌细胞系中不明显。结直肠癌CSCs通过基质胶和胎牛血清诱导分化。用抗癌药物处理的分化CSCs未显示FBXW7上调,并且对伊立替康(CPT-11)更敏感,突出了我们数据潜在的CSC特异性性质。在化疗后的CRC患者切除的肝转移部位进一步验证了FBXW7的过表达。总之,我们的研究表明,一种CSC特异性的FBXW7调节机制与对化疗药物的抗性密切相关。化疗后抑制CSCs中FBXW7的上调可能增强对抗癌药物的反应,并代表了一种消除结直肠癌CSCs的有吸引力的策略。《干细胞》2017年;35:2027 - 2036。